Concepedia

Rongqing Pan

RP

12

Publications

1.8K

Citations

12

H-Index

2011

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Harvard University

First Affiliated Hospital of Harbin Medical University

Chinese Academy of Medical Sciences & Peking Union Medical College

Rongqing Pan is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and cell death.

ORCID

Top concepts

Publications per year

2011–2022

12

Publications

12

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Rongqing Pan, Leah J. Hogdal, Juliana M. Benito et al. · Cancer Discovery · 2013 · 717 citations · Full text

Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy

Rongqing Pan, Vivian Ruvolo, Hong Mu et al. · Cancer Cell · 2017 · 299 citations · Full text

, , +8

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis

Rongqing Pan, Jeremy Ryan, Deng Pan et al. · Cell · 2022 · 179 citations · Full text

, , +7

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Qi Zhang, Bridget Riley‐Gillis, Lina Han et al. · Signal Transduction and Targeted Therapy · 2022 · 168 citations · Full text

Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia

Rongqing Pan, Vivian Ruvolo, Jun Wei et al. · Blood · 2015 · 136 citations · Full text

Rows per page

1–5 of 12